The difference in prognosis of stage II and III colorectal cancer based on preoperative serum tumor markers

You, Weiqiang; Sheng, Nengquan; Li, Yan; Chen, Hongqi; Gong, Jianfeng; Zheng-hui, HE; Zheng, Kaiwen; Chen, Zhaohuan; Wang, Yafang; Tan, Gewen; Xie, Lu; Wang, Zhigang

doi:10.7150/jca.31660

Cited by 25 publications

(24 citation statements)

References 28 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, many studies have demonstrated that CA242 works well in predicting the diagnosis, progression, and prognosis of colorectal cancer in combination with other tumor markers [18,19,26,30]. Our results showed that the mean value in colorectal cancer was 26.50±59.58 and that the AUC was 0.7241 (0.7073, 0.7408) ( Table 1), which was consistent with previous studies [22,26,27].…”

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

“…CA242 is not merely a diagnostic predictor [12,13] but also participates in forecasting the progression and prognosis of many tumors [14][15][16]. In pancreatic cancer, colorectal cancer [17][18][19], gastric cancer [20,21] and other tumors and when used alone or in combination with CA19-9, CA50, CEA and other biomarkers [4,7,14,[22][23][24], CA242 is gradually becoming better understood and applied more broadly. Therefore, CA242 is routinely included in screening and monitoring many different cancers.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Serum CA242: a biomarker for diagnosis, progression, and metastasis in multiple tumors

Shen

Qin

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundCA242 is a classic biomarker used for diagnosing digestive tract tumors, especially pancreatic cancer. However, CA242 serum levels in some tumor patients and what might influence these levels remain unknown or uncertain. This study aimed to reveal the pancancer landscape of serum CA242 levels and identify some influencing factors.MethodsIn the current study, serum CA242 levels and clinical information, including clinical stage and metastatic status, were collected from 37,493 patients with 35 different types of neoplastic disease, and CA242 values were also obtained for 880 healthy controls.ResultsSerum CA242 levels in patients with one of 21 different cancers were significantly higher than those in healthy controls and had diagnostic value in 9 tumors (AUC>0.7, P<0.05); serum CA242 levels were increased across all malignant digestive tract tumors. Compared to patients without metastasis, cancer patients with one of 15 kinds of cancer with lymph node metastasis and distant metastasis showed elevated CA242 levels. Moreover, CA242 was helpful in distinguishing the clinical stage and metastatic status in 6 cancers. In addition, the presence of multiple metastases and liver metastasis might result in increased CA242 levels.ConclusionsOverall, CA242 can not only serve as a diagnostic biomarker for malignant tumors in the digestive system but also predict the progression, stage, and metastasis of many other tumors that have not received clinical attention.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum CA242: a biomarker for diagnosis, progression, and metastasis in multiple tumors

Shen

Qin

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Therefore, in clinical practice, should we refer to the levels of perioperative serum CEA when we give patients treatment recommendations? In addition, we also found that the number of preoperative elevated tumor markers also had important impact on the prognosis of CRC, including CEA, CA19-9, CA242, and CA125 (28). We believe that serum tumor markers have great value in CRC, but these markers have not been paid enough attention in the clinic.…”

Section: Discussionmentioning

confidence: 93%

Clinical Significances of Positive Postoperative Serum CEA and Post-preoperative CEA Increment in Stage II and III Colorectal Cancer: A Multicenter Retrospective Study

You

Cai

et al. 2020

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

Background: Carcinoembryonic antigen (CEA) is the most common serum tumor marker in colorectal cancer (CRC). Nevertheless, few previous studies demonstrated the impacts of postoperative CEA and post-preoperative CEA increment on prognosis of CRC. Methods: Patients with stage II and III CRC were included from January 2009 to December 2015. All clinical and follow-up data were collected. Patients were divided into four different groups according to the levels of postoperative serum CEA and post-preoperative CEA trends. Chi-square test was used to analyze the relationship between clinical variables and categorized postoperative CEA and CEA increment. Cox proportional hazard regression was used for univariate and multivariable analyses. The log-rank test was performed to compare PFS and OS among groups. Results: Patients, 1,008, who underwent radical surgery, were enrolled. Our results showed that positive postoperative CEA and CEA increment were related to clinical stage, T stage, N stage, tumor differentiation, and lymphatic invasion (p < 0.05). Univariate and multivariable analysis results suggested that positive postoperative CEA and CEA increment were independent prognostic factors for PFS (HR = 3.149, 95% CI, 2.426-4.088, p = 0.000 for postoperative CEA; HR = 2.708, 95% CI, 2.106-3.482, p = 0.000 for CEA increment) and OS (HR = 3.414, 95% CI, 2.549-4.574, p = 0.000 for postoperative CEA; HR = 2.373, 95% CI, 1.783-3.157, p = 0.000 for CEA increment). The survival analyses revealed positive postoperative CEA, and CEA increment predicted worse prognosis. Furthermore, our results indicated that the 3-and 5-year PFS rates were 86.6 and 78.4% in group A, but decreased to 25.3 and 7.2% in group D (p < 0.001). Similarly, the 3-and 5-year OS rates for group A were 92.5 and 83.9%, much higher than group D (p < 0.001). In other words, patients with both postoperative CEA elevation and CEA increment had the worst prognosis. You et al. Positive Post-CEA and Post-preoperative CEA Increment Conclusions: Positive postoperative CEA and CEA increment were independent prognostic factors for stage II and III CRC. Additionally, postoperative CEA and CEA increment had significant impacts on PFS and OS of CRC.

show abstract

“…CA242 has been reported to be more sensitive and speci c than CA50 and CEA in Dukes' A-D colorectal cancer [22], in addition to its considerable value in predicting recurrence and metastasis in clinical stage II and III colorectal cancer [18]. Moreover, many studies have demonstrated that CA242 works well in predicting the diagnosis, progression, and prognosis of colorectal cancer in combination with other tumor markers [18,19,26,30]. Our results showed that the mean value in colorectal cancer was 26.50 ± 59.58 and that the AUC was 0.7241 (0.7073, 0.7408) (Table 1), which was consistent with previous studies [22,26,27].…”

Section: Page 14/19mentioning

confidence: 99%

Serum CA242: a biomarker for diagnosis, progression, and metastasis in multiple tumors

Shen

Qin

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background CA242 is a classic biomarker used for diagnosing digestive tract tumors, especially pancreatic cancer. However, CA242 serum levels in some tumor patients and what might influence these levels remain unknown or uncertain. This study aimed to reveal the pancancer landscape of serum CA242 levels and identify some influencing factors. Methods In the current study, serum CA242 levels and clinical information, including clinical stage and metastatic status, were collected from 37,493 patients with 35 different types of neoplastic disease, and CA242 values were also obtained for 880 healthy controls. Results Serum CA242 levels in patients with one of 21 different cancers were significantly higher than those in healthy controls and had diagnostic value in 9 tumors (AUC > 0.7, P < 0.05); serum CA242 levels were increased across all malignant digestive tract tumors. Compared to patients without metastasis, cancer patients with one of 15 kinds of cancer with lymph node metastasis and distant metastasis showed elevated CA242 levels. Moreover, CA242 was helpful in distinguishing the clinical stage and metastatic status in 6 cancers. In addition, the presence of multiple metastases and liver metastasis might result in increased CA242 levels. Conclusions Overall, CA242 can not only serve as a diagnostic biomarker for malignant tumors in the digestive system but also predict the progression, stage, and metastasis of many other tumors that have not received clinical attention.

show abstract

The difference in prognosis of stage II and III colorectal cancer based on preoperative serum tumor markers

Cited by 25 publications

References 28 publications

Serum CA242: a biomarker for diagnosis, progression, and metastasis in multiple tumors

Serum CA242: a biomarker for diagnosis, progression, and metastasis in multiple tumors

Clinical Significances of Positive Postoperative Serum CEA and Post-preoperative CEA Increment in Stage II and III Colorectal Cancer: A Multicenter Retrospective Study

Serum CA242: a biomarker for diagnosis, progression, and metastasis in multiple tumors

Contact Info

Product

Resources

About